Use of class I histone deacetylase inhibitor romidepsin in combination regimens.

Abstract

Histone deacetylase (HDAC) inhibitors are epigenetic-modifying agents that have shown promise as anticancer therapies. Several HDAC inhibitors have been approved by the US Food and Drug Administration (FDA) as single-agent therapies to treat T-cell lymphoma. The synergistic combination of HDAC inhibitors with other anticancer agents has the potential to constitute treatment regimens with enhanced efficacy. Romidepsin is a structurally unique, potent, bicyclic class 1 selective HDAC inhibitor approved by the FDA for the treatment of patients with peripheral T-cell lymphoma who have had at least 1 prior therapy and patients with cutaneous T-cell lymphoma who have had at least 1 prior systemic therapy. Here, we review data that support the use of romidepsin in combination with other anticancer agents for the treatment of various malignancies. Promising results have emerged from early clinical studies, supporting the potential for romidepsin combination regimens to constitute safe and effective treatments for cancer.

• Authors: Adam Petrich, Chadi Nabhan
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 57 Issue 8 Pg. 1755-65 (08 2016) ISSN: 1029-2403 [Electronic] United States
• PMID: 27118119 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Depsipeptides
• Histone Deacetylase Inhibitors
• Proteasome Inhibitors
• romidepsin

Topics

• Antineoplastic Agents (pharmacology, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Clinical Trials as Topic
• Depsipeptides (pharmacology, therapeutic use)
• Drug Synergism
• Epigenesis, Genetic (drug effects)
• Histone Deacetylase Inhibitors (pharmacology, therapeutic use)
• Humans
• Lymphoma, T-Cell (drug therapy)
• Proteasome Inhibitors (pharmacology, therapeutic use)